Dalpiciclib Plus Letrozole and Capecitabine
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Advanced Breast Cancer
Related studies linked through entity extraction aliases.
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE4
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
- Status
- UNKNOWN
- Phase
- PHASE3
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
- Status
- UNKNOWN
- Phase
- PHASE3
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Rehabilitation for People With Advanced Cancer
- Status
- COMPLETED
- Phase
- NA
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
A Study to Investigate LYL797 in Adults With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
- Status
- UNKNOWN
- Phase
- N/A
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
A Study of Lerociclib in Participants With Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2